Alzheimer's disease

Development and assessment of psychoeducational group interactions: 1) for individuals with Alzheimer Disease who have lost their driving privileges and 2) for their primary caregivers.

Novartis Pharmaceuticals Canada Inc., Dorval, QC, has announced that the government of Ontario has agreed to list Exelon(x), a new symptomatic treatment for mild to moderate Alzheimer Disease (AD), on the Ontario Drug Benefit Formulary as a Limited Use Benefit effective March 7, 2001.

This review provides an overview of the epidemiologic evidence for environmental etiologies for neurodegenerative diseases such as Alzheimer disease, Parkinson disease, parkinsonian syndromes (multiple system atrophy and progressive supranuclear palsy), and amyotrophic lateral sclerosis.

Clumps of large, sticky proteins forming senile plaques have been observed in the brains of people with Alzheimer disease ever since neurologist Alois Alzheimer first described the disorder nearly a century ago.